Document:

WWW.EXFILE.COM -- DATAWATCH CORP. -- FORM 8-K -- EXHIBIT 10.1 -- 15336

    EXHIBIT
      10.1

    

     

    
      DATAWATCH
        CORPORATION

       

      Restricted
        Stock Unit Agreement for Directors

      

      Datawatch
        Corporation, a Delaware
        corporation (the “Company”), hereby grants as of the award date below (“Award
        Date”) to the director named below (the “Participant”), and the Participant
        hereby accepts, an award (“Award”) of Restricted Stock Units (“RSU”) that will
        vest as described in the Vesting Schedule below, such Award to be subject
        to the
        terms and conditions specified in the attached Exhibit A.

       

      
 

      
        	
                Participant
                  Name:

                

                Award
                  Date:

                

                Number
                  of RSUs:

                

                Vesting
                  Schedule:

                

                Vesting
                  Date 

              	
                _____________________________________

                 

                
                  _____________________________________

                   

                

                _____________________________________

                 

                 

                Number
                  of RSUs 

              

      

       

      
 

      

      By
        signing this Agreement, the Participant acknowledges receipt of a copy of
        this
        Agreement and a copy of the 2006 Equity Compensation and Incentive Plan and
        the
        Prospectus related thereto.

      

       This
        Agreement will be effective only upon execution by the Participant and delivery
        of such signed Agreement to the Company.

      

      IN
        WITNESS WHEREOF, the Company and the
        Participant have caused this instrument to be executed as of the Award Date
        set
        forth above.

      

      
        	 	 
	
                 

                ___________________________

              	
                DATAWATCH
                  CORPORATION

              
	
                (Participant
                  Signature)

              	 
	 	 
	 	 
	
                 

                ___________________________

              	 
	
                (Street
                  Address)

              	
                By:__________________________________

              
	 	
                Name:

              
	
                ___________________________

                (City/State/Zip
                  Code)

              	
                Title:

              

      

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      Exhibit
        A

      

      Restricted
        Stock Unit Agreement for Directors

      Terms
        and Conditions

      

      1.  Award.  The
        Participant is hereby granted an Award of RSUs, effective as
        of the date set forth on the cover page attached hereto
        (the “Award Date”), subject to the terms and conditions set forth herein
        (collectively with the cover page, the “Agreement”), and subject to and governed
        by the Company’s 2006 Equity Compensation and Incentive Plan (the
“Plan”).  Capitalized terms not otherwise defined herein shall have
        the meanings ascribed to them in the Plan. Each RSU represents the right
        to
        receive one share of the Company’s Common Stock upon the satisfaction of terms
        and conditions set forth in this Agreement and the Plan.

       

      2.  Vesting.  Except
        as set forth in Section 6 herein, the RSUs will remain restricted and may
        not be
        sold, assigned, exchanged, pledged or otherwise transferred by the Participant
        until the RSUs have become vested pursuant to the terms of this
        Agreement.  If the Participant has continued to serve the Company in
        the capacity of a director, then the RSUs will vest as provided on the cover
        page hereto. Each date on which a portion of the Award
        vests shall be referred to herein as a “Vesting
        Date.” Notwithstanding the foregoing, in accordance with
        and subject to the provisions of the Plan, the Committee may, in its discretion,
        accelerate the date that any installment of this RSU becomes vested.

       

      3.  Acceleration
        of Vesting Upon Change of Control.  Notwithstanding
        Section 2 hereof, in the event of a Change in Control (as defined below) of
        the Company while this RSU is in effect, this RSU shall, immediately prior
        to
        the consummation of such Change in Control, become fully vested and all shares
        subject to this RSU shall be delivered to the Participant; provided,
however, that the Board, in its sole discretion, may require that
        the
        Participant’s rights under this Section 3 shall be conditioned on approval by
        the stockholders of the Company in accordance with Section 280G(b)5(B) of
        the
        Code and regulations thereunder.  For purposes of this Agreement, a
“Change in Control” means the occurrence of any of the following
        events:

       

      (a)  The
        Company is merged or consolidated or reorganized into or with another
        corporation or other legal person, and as a result of such merger, consolidation
        or reorganization less than a majority of the combined voting power of the
        then-outstanding securities of such surviving, resulting or reorganized
        corporation or person immediately after such transaction is held in the
        aggregate by the holders of the then-outstanding securities entitled to vote
        generally in the election of directors of the Company ("Voting Stock")
        immediately prior to such transaction;

       

      (b)  The
        Company sells or otherwise transfers all or substantially all of its assets
        to
        any other corporation or other legal person, and as a result of such sale
        or
        transfer less than a majority of the combined voting power of the
        then-outstanding securities of such corporation or person immediately after
        such
        sale or transfer is held in the aggregate by the holders of Voting Stock
        of the
        Company immediately prior to such sale or transfer;

       

      (c)  There
        is
        a report filed on Schedule 13D or Schedule 14D-1 (or any successor
        schedule, form or report), each as promulgated pursuant to the Securities
        Exchange Act of 1934, as amended (the “Exchange Act”), disclosing that any
        "person" (as such term is used in Section 13(d)(3) or Section 14(d)(2)
        of the Exchange Act) has become the "beneficial owner" (as such term is used
        in
        Rule 13d-3 under the Exchange Act) of securities representing 50% or more
        of the
        Voting Stock of the Company;

       

      (d)  The
        Company files a report or proxy statement with the Securities and Exchange
        Commission pursuant to the Exchange Act disclosing in response to Form 8-K
        or
        Schedule 14A (or any successor schedule, form or report or item therein)
        that a change in control of the Company has occurred; or

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      (e)  If
        during
        any period of two consecutive years, individuals who at the beginning of
        any
        such period constitute the Board cease for any reason to constitute at least
        a
        majority thereof, unless the election, or the nomination for election by
        the
        Company’s stockholders, of each director of the Company first elected during
        such period was approved by a vote of at least a majority of the directors
        then
        still in office who were directors of the Company at the beginning of any
        such
        period;

       

      provided,
        however, that a “Change in Control” shall not be deemed to have occurred
        for purposes of this Agreement solely because (x) the Company, (y) an
        entity in which the Company directly or indirectly beneficially owns 50%
        or more
        of the voting securities, or (z) any Company-sponsored employee stock
        ownership plan or any other employee benefit plan of the Company, either
        files
        or becomes obligated to file a report or a proxy statement under or in response
        to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A
        (or any successor schedule, form or report) under the Exchange Act, disclosing
        beneficial ownership by it of shares of Voting Stock or because the Company
        reports that a change in control of the Company has occurred by reason of
        such
        beneficial ownership.

       

      4.  Distribution
        of the Award; Dividend Equivalents.  As soon as reasonably
        practicable following each Vesting Date, the Company will release the portion
        of
        the Award that has become vested as of such Vesting Date in the form of shares
        of the Company’s Common Stock.  The Company shall provide the
        Participant with at least seven (7) days written notice prior to the Vesting
        Date; such notice to specify the amount that the Participant is required
        to pay
        to satisfy any applicable withholding Taxes (as hereinafter below). The
        Participant may deposit with the Company an amount of cash equal to the amount
        determined by the Company, utilizing a tax rate determined by the Company
        in its
        reasonable discretion, to be required with respect to any withholding taxes,
        FICA contributions, or the like under any national, federal, state, local
        or
        other statute, ordinance, rule, or regulation in connection with the award
        or
        settlement of the restricted stock units (the
“Taxes”).  Alternatively, if the Company does not receive such amount
        from the Participant at least two (2) days prior to the Vesting Date, the
        Company will withhold a number of shares (rounded up to the nearest whole
        share)
        of the Company’s Common Stock with a market value determined as of the close of
        business on the business day immediately preceding the Vesting Date) equal
        to
        the amount of such Taxes associated with the vesting or settlement of the
        Award;
provided, however, that the Company shall not be liable for determining
        the exact number of shares.

       

      The
        Participant shall have the right to receive dividend equivalent payments
        with
        respect to the Common Stock subject to the Award as provided in this
        paragraph.  Upon each Vesting Date, Participant shall be entitled to
        receive a dividend equivalent payment in respect of the shares of Common
        Stock
        covered by the Award that are not vested on the record date for each dividend
        payment, if any, made by the Company on its Common Stock for which the record
        date occurred (i) on or after the Award Date or the immediately preceding
        Vesting Date, as the case may be, and (ii) prior to the applicable Vesting
        Date,
        in an amount in cash equal to the amount of any dividend which otherwise
        would
        have been paid to the Participant if such unvested shares had been issued
        for
        the benefit of the Participant on the record dates for such dividend payments,
        subject to any applicable withholding for Taxes.  Such dividend
        equivalent payments may be settled by the Company subject to such other
        conditions or terms that the Committee may establish. Except for dividend
        equivalent payments, the Participant shall have no rights as a stockholder,
        including voting rights, with respect to the RSUs.

      

      5.  Termination
        of Relationship with the Company.  If the Participant ceases
        to be a director of the Company, for any reason, any portion of the Award
        that
        has not become vested on or prior to the date of such cessation shall
        immediately be forfeited.

       

       

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      6.  Award
        Not Transferable.  The Award will not be assignable or
        transferable by the Participant, except by operation of law, or by will or
        the
        laws of descent and distribution.

       

      7.  Transferability
        of Award Shares.  Until registered under the Securities Act
        of 1933, as amended, or any successor statute (the “Securities Act”), the shares
        of Common Stock represented by the RSUs will be of an illiquid nature and
        will
        be deemed to be “restricted securities” for purposes of the Securities
        Act.  Accordingly, such shares must be sold in compliance with the
        registration requirements of the Securities Act or an exemption
        therefrom.  The Company reserves the right to place restrictions
        required by law on any shares of the Company’s Common Stock received by the
        Participant pursuant to the Award.

       

      8.  Conformity
        with the Plan.  The Award is intended to conform in all
        respects with, and is subject to applicable provisions of, the Plan. To the
        extent that any provision of this Agreement conflicts with the express terms
        of
        the Plan, it is hereby acknowledged and agreed that the terms of the Plan
        shall
        control and, if necessary, the applicable provisions of this Agreement shall
        be
        deemed to be amended so as to carry out the purpose and intent of the Plan.
        By
        the Participant’s acceptance of this Agreement, the Participant agrees to be
        bound by all of the terms of this Agreement and the
        Plan.  Notwithstanding any other provision of this Section 8, in the
        event that the provisions of this Agreement are subject to Section 409A of
        the
        Internal Revenue Code of 1986, as amended, and the Treasury Regulations
        promulgated thereunder (“Section 409A”), the provisions of this Agreement shall
        comply with, and shall be interpreted in a manner consistent with, Section
        409A.

       

      9.  No
        Rights to Continued Board Service.  Nothing in this Agreement
        confers any right on the Participant to continue as a director of the Company
        or
        a Subsidiary or affects in any way the right of any of the Company or a
        Subsidiary to terminate any such relationship of the Participant.

       

      10.   
        Miscellaneous.

       

      (a)           Notices.  All
        notices hereunder shall be in writing and shall be deemed given when sent
        by
        certified or registered mail, postage prepaid, return receipt requested,
        if to
        the Participant, to the address set forth above or at the address shown on
        the
        records of the Company, and if to the Company, to the Company’s principal
        executive offices, attention of the Chief Financial Officer.

      

      (b)           Entire
        Agreement; Modification.  This Agreement, together with the
        Plan, constitutes the entire agreement between the parties relative to the
        subject matter hereof, and supersedes all proposals, written or oral, and
        all
        other communications between the parties relating to the subject matter of
        this
        Agreement.  The Company may amend, suspend or terminate the Plan, this
        Agreement and the Award granted hereunder at any time; provided, however,
        that
        no such amendment, suspension or termination may materially impair any Award
        without the Participant’s written consent.

      

      (c)           
        Fractional Shares.  If the shares under this Award
        become issuable for a fraction of a share because of the adjustment provisions
        contained in the Plan, such fraction shall be rounded down to the nearest
        whole
        share.

      

      (d)           Severability.  The
        invalidity, illegality or unenforceability of any provision of this Agreement
        shall in no way affect the validity, legality or enforceability of any other
        provision.

      

      (e)  
Successors
        and Assigns.  Except as provided herein, this Agreement shall
        be binding upon and inure to the benefit of the parties hereto and their
        respective successors and assigns, subject to the limitations set forth in
        Section 6 hereof.

       

       

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      
 

      (f)           
        Governing Law.  This Agreement shall be governed by
        and interpreted in accordance with the laws of the Commonwealth of
        Massachusetts, without giving effect to the principles of the
        conflicts of laws thereof.

      

      (g)           Data
        Protection Waiver.  The Participant understands and consent
        to the Company or its agents or independent contractors appointed to administer
        the Plan obtaining certain of the Participant’s personal employment information
        required for the effective administration of the Plan and that such information
        may be transmitted outside of the country of the Participant’s employment and/or
        residence.

       

      
 

      [Remainder
        of Page Intentionally Left Blank]WWW.EXFILE.COM, INC. -- MATRITECH, INC. -- EXHIBIT 4.1 TO FORM 8-K

    EXHIBIT
      4.1

    

    AGREEMENT
      AND AMENDMENT TO 15% SECURED CONVERTIBLE PROMISSORY NOTES DATED

    JANUARY
      13, 2006 AND DATED JANUARY 22, 2007

    

    This
      Agreement and Amendment is executed and delivered on this 27th day of July
      2007
      by and among Matritech, Inc. (the “Borrower”), the undersigned
      holders of a majority of the outstanding principal amount of those certain
      15%
      Secured Convertible Promissory Notes issued by the Borrower on January 13,
      2006
      (the “Series A Notes”) pursuant to the Securities Purchase
      Agreement, dated as of January 13, 2006, by and among the Borrower and the
      purchasers party thereto (the “Series A Purchase Agreement”)
      and the undersigned holders of a majority of the outstanding principal amount
      of
      those certain 15% Secured Convertible Promissory Notes issued by the Borrower
      on
      January 22, 2007 (the “Series B Notes”) pursuant to the
      Securities Purchase Agreement, dated as of January 22, 2007, by and among the
      Borrower and the purchasers party thereto (the “Series B Purchase
      Agreement”).  The undersigned holders of a majority of the
      outstanding principal amount of the Series A Notes shall be referred to as
      the
“Series A Majority Holders.”  The
      undersigned holders of a majority of the outstanding principal amount of the
      Series B Notes shall be referred to as the “Series B
Majority Holders.”  All
      capitalized terms used in this Agreement and Amendment but not otherwise defined
      herein shall have the meanings ascribed to such terms in the Series A Purchase
      Agreement and the Series B Purchase Agreement, respectively.

    

    WHEREAS,
      the parties have determined that it is in the best interests of the Borrower
      and
      all the holders of the Series A Notes and all the holders of the Series B Notes
      that the following agreements and amendments be made.

    

    NOW,
      THEREFORE, for good and valuable consideration, the receipt and legal
      sufficiency of which is hereby acknowledged, the parties agree as
      follows:

    

    1.           The
      provisions of Article VIII.C(iii) of the Series A Notes and the Series B Notes
      are hereby deleted in their entirety and replaced with the
      following:

    

    “(iii)       redeem,
      repurchase or otherwise acquire, or declare or pay any cash dividend or
      distribution on, any securities of the Borrower, except (a) the Borrower may
      redeem all outstanding warrants of the Borrower originally issued by the
      Borrower on March 31, 2003 on such terms as its Board of Directors may
      establish, (b) pursuant to any equity compensation plan approved by the
      Borrower’s Board of Directors or (c) as expressly required by the terms of the
      Series A Notes or the Series B Notes;”

    

    5.           Except
      as expressly set forth herein, (a) the original terms and conditions of the
      Series A Notes, as previously amended on January 22, 2007, shall remain in
      full
      force and effect; (b) this Agreement and Amendment shall not be deemed to be
      a
      waiver, amendment or modification of, or consent to or departure from, any
      provision of the Series A Notes or to be a waiver of any Event of Default
      whether arising before or after the date hereof as a result of the transactions
      contemplated hereby; and (c) this Agreement and Amendment shall not preclude
      the
      future exercise of any right, remedy, power or privilege available to the
      holders of the Series A Notes whether under the Series A 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Notes
      or
      otherwise, and shall not be construed or deemed to be a satisfaction, novation,
      cure, modification, amendment or release of the Series A Notes.

    

    6.  
Except
      as
      expressly set forth herein, (a) the original terms and conditions of the Series
      B Notes shall remain in full force and effect; (b) this Agreement and Amendment
      shall not be deemed to be a waiver, amendment or modification of, or consent
      to
      or departure from, any provision of the Series B Notes or to be a waiver of
      any
      Event of Default whether arising before or after the date hereof as a result
      of
      the transactions contemplated hereby; and (c) this Agreement and Amendment
      shall
      not preclude the future exercise of any right, remedy, power or privilege
      available to the holders of the Series B Notes whether under the Series B Notes
      or otherwise, and shall not be construed or deemed to be a satisfaction,
      novation, cure, modification, amendment or release of the Series B
      Notes.

    

    7.           This
      Agreement and Amendment (a) constitutes the entire understanding of the parties
      with respect to the subject matter hereof, and any other prior agreements,
      whether written or oral, with respect hereto or thereto are expressly superseded
      hereby; (b) shall be governed by and construed in accordance with the laws
      of
      the State of Delaware without regard to principles of conflicts of laws; and
      (c)
      shall be binding upon and inure to the benefit of the successors and assigns
      of
      the Borrower and all the holders of the Series A Notes and all the holders
      of
      the the Series B Notes.

    

    7.  
This
      Agreement and Amendment may be executed in multiple counterparts, each of which
      shall be deemed an original but all of which together shall constitute one
      and
      the same instrument, and by facsimile transmission, which facsimile signatures
      shall be considered original executed counterparts.

    

    8.  
All
      references to the “Notes” in the Series A Purchase Agreement or any documents or
      instruments executed by Borrower in connection therewith shall be deemed to
      refer to the Series A Notes as the same have been amended through the date
      hereof.  All references to the “Notes” in the Series B Purchase
      Agreement or any documents or instruments executed by Borrower in connection
      therewith shall be deemed to refer to the Series B Notes as the same have been
      amended through the date hereof.

    

    9.  
Each
      holder of the Series A Notes is directed to attach this Agreement and Amendment
      to its Series A Note, provided that the failure to so attach this
      Agreement and Amendment to any Series A Note shall not affect in any way the
      enforceability hereof or of any Series A Note.  Each holder of the
      Series B Notes is directed to attach this Agreement and Amendment to its Series
      B Note, provided that the failure to so attach this Agreement and
      Amendment to any Series B Note shall not affect in any way the enforceability
      hereof or of any Series B Note.

    

    10.        
      Any
      provision of this Agreement and Amendment that is prohibited or unenforceable
      in
      any jurisdiction shall be ineffective to the extent of such prohibition or
      unenforceability without invalidating the remaining provisions hereof in that
      jurisdiction or affecting the validity or enforceability of such provision
      in
      any other jurisdiction.

     

     

    
 

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    11.        
      The
      Borrower hereby represents and warrants to the Series A Majority Holders and
      the
      Series B Majority Holders as follows:

    

    (a)           Borrower
      has the corporate power and authority to execute, deliver, and perform this
      Agreement and Amendment and all such action has been duly and validly authorized
      by all necessary corporate proceedings on its part.

    

    (b)           The
      Series A Notes and the Series B Notes, as amended hereby, constitute the legal,
      valid and binding agreements of the Borrower, enforceable in accordance with
      their respective terms, except as such enforceability may be limited by
      bankruptcy, insolvency, moratorium or other similar laws affecting creditors’
rights generally and by general principles of equity.

    

    (c)           The
      Borrower has, and will have after giving effect to this Agreement and Amendment,
      no claims, defenses or set-offs to its obligations under the Series A Notes
      and
      Series B Notes.

     

     

     

    
 

    

    [Remainder
      of Page Intentionally Left Blank]

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the undersigned Borrower and the Series A Majority Holders
      and
      the Series B Majority Holders have caused this Agreement and Amendment to be
      executed as of the day first above written.

    

    Borrower:

    

    Matritech,
      Inc.

    

    By:
      _____________________________

    Name:   Stephen
      D.
      Chubb

    Title:     Chief
      Executive Officer

    

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    

      [Signature
        Page to Agreement and Amendment]

    

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the Series A Majority Holders
      and
      Series B Majority Holders have caused this Agreement and Amendment to be
      executed as of the day first above written.

     

     

    
      	
               

            	
              Holders:

            

    

    

    SDS
      Capital Group SPC, Ltd., on behalf of its Class D
      segregated portfolio

    

    By:
      ______________________________

    Name:  
      Steve Derby

    Title:     Director

    
      	
               

            	
              Series
                A Notes Held:
                $1,323,333  principal

            

    

    
      	
               

            	
              Series
                B Notes Held: $1,140,000 principal

            

    

    

     

    
 

    ProMed
      Partners, L.P.

    

    By:
      ______________________________

    Name:   David
      B. Musket

    Title:     Managing
      Director

    
      	
               

            	
              Series
                A Notes Held:
                $131,476  principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $320,399  principal

            

    

    

     

    
 

    ProMed
      Partners II, L.P.

    

    By:
      ______________________________

    Name:   David
      B. Musket

    Title:     Managing
      Director

    
      	
               

            	
              Series
                B Notes Held:
                $16,816  principal

            

    

    

     

    
 

    ProMed
      Offshore Fund, Ltd.

    

    By:
      ______________________________

    Name:   David
      B. Musket

    Title:     Managing
      Director

    
      	
               

            	
              Series
                A Notes Held: $22,539 principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $48,072  principal

            

    

    

     

     

     

     

     

    

      [Signature
        Page to Agreement and Amendment]

    

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the Series A Majority Holders
      and
      Series B Majority Holders have caused this Agreement and Amendment to be
      executed as of the day first above written.

     

    
 

    ProMed
      Offshore Fund II, Ltd.

    

    By:
      ______________________________

    Name:   
      David B. Musket

    Title:      Managing
      Director

    
      	
               

            	
              Series
                A Notes Held:
                $835,569  principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $414,713  principal

            

    

    

    

     

    David
      B. Musket, Individually

    

    

    _________________________________

    
      	
               

            	
              Series
                A Notes Held: $106,875 principal

            

    

    
      	
               

            	
              Series
                B Notes Held: $250,000 principal

            

    

    

    
 

    

    H&Q
      Life Science Investors

    

    By:
      ______________________________

    Name:    Dan
      Omstead

    Title:      President

    
      	
               

            	
              Series
                A Notes Held:
                $1,583,333  principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $1,000,000  principal

            

    

     

     

    
 

    The
      term
      H&Q Life Sciences Investors is the designation of the Trustees for the time
      being under a Declaration of Trust dated February 20, 1992, as amended, and
      all
      persons dealing with H&Q Life Sciences Investors must look solely to the
      trust property for the enforcement of any claims against H&Q Life Sciences
      Investors, and neither the Trustees, officers nor shareholders assume any
      personal liability for the obligations entered into on behalf of H&Q Life
      Sciences Investors.

    

    

    

     

     

     

     

     

     

     

     

     

     

     

    
       

      

        [Signature
          Page to Agreement and Amendment]

      

      
        
          
          

        

        
          6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]